Lantern Pharma (LTRN) Change in Acquisitions & Divestments (2022 - 2026)

Lantern Pharma (LTRN) has 5 years of Change in Acquisitions & Divestments data on file, last reported at $4.2 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 48.32% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.8 million (down 6.9% YoY) and the FY2025 annual result came in at $25.8 million, up 24.8% from the prior year.
• Change in Acquisitions & Divestments climbed to $4.2 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $8.2 million in Q1 2025 to a low of $176519.0 in Q1 2022.
• A 5-year average of $3.7 million and a median of $2.5 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments jumped 1118.0% — and 2026, when it tumbled 48.32%.
• Tracing LTRN's Change in Acquisitions & Divestments over 5 years: stood at $1.2 million in 2022, then soared by 51.39% to $1.8 million in 2023, then surged by 78.86% to $3.2 million in 2024, then slipped by 23.04% to $2.5 million in 2025, then surged by 69.96% to $4.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $4.2 million (Q1 2026), $2.5 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.